pufa 18:3 c

PUFA 18:3 c, more commonly known as alpha‑linolenic acid (ALA), is a type of polyunsaturated fatty acid (PUFA) that contains 18 carbon atoms and three cis double bonds, classifying it as an omega‑3 (n‑3) fatty acid. ALA is essential, meaning the human body cannot synthesize it and must obtain it through dietary intake. Structurally, ALA is denoted as 18:3 n‑3, indicating the first double bond occurs three carbons from the methyl end. This fatty acid is predominantly found in plant‑based foods including certain seeds, nuts, and vegetable oils such as flaxseed oil, chia seeds, walnuts, soybean oil, and canola oil. The biochemical significance of ALA lies not only in its own metabolic functions but also as a precursor for the longer chain omega‑3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have potent roles in anti‑inflammatory processes and cell membrane composition. Although conversion rates of ALA to EPA and DHA are relatively low in humans, the intake of ALA contributes to the overall omega‑3 fatty acid pool and supports health outcomes such as cardiovascular health, neural function, and regulation of inflammation. Early research into essential fatty acids identified the inability of higher organisms to synthesize certain PUFA de novo, which led to the classification of ALA and linoleic acid as essential due to their necessity in the diet to prevent deficiency syndromes. ALA’s presence in cell membranes influences fluidity and function, particularly in tissues with high metabolic demand, such as the brain and retina. While dietary focus often centers on EPA and DHA from marine sources, ALA remains a critical nutritional component, especially for individuals following plant‑based diets. The Food and Nutrition Board established Adequate Intake levels for ALA due to its recognized role in human nutrition and the difficulty in establishing a true RDA based on available evidence.

Alpha‑linolenic acid (ALA) is a multifaceted nutrient that contributes to a variety of physiological functions. As a polyunsaturated omega‑3 fatty acid, it is incorporated into cell membranes where it influences membrane fluidity, receptor function, and signaling pathways. One of the primary roles of ALA is serving as a metabolic precursor to longer chain omega‑3 fatty acids such as EPA and DHA, which are involved in the production of anti‑inflammatory eicosanoids and protectins. Multiple cohort studies and systematic reviews have examined the association of ALA intake with reduced cardiovascular disease (CVD) outcomes. A dose‑response meta‑analysis of prospective cohorts reported that higher dietary ALA intake was associated with a lower risk of coronary heart disease mortality, demonstrating a protective cardiovascular effect. Mechanistically, ALA and its metabolites may reduce inflammation, improve endothelial function, and favorably modulate lipid profiles. Additionally, evidence suggests that diets rich in omega‑3 PUFAs, including ALA, correlate with lower systemic inflammation markers and improved vascular function, reflecting potential benefits for heart health. Another beneficial aspect of ALA is its role in maintaining healthy skin and barrier function. Essential fatty acids contribute to the structural integrity of the epidermal lipid barrier, aiding in moisture retention and protecting against environmental damage. Insufficient intake can lead to skin dryness and inflammation, indicative of essential fatty acid deficiency. Emerging evidence also explores the role of ALA in cognitive health and neural development. Although EPA and DHA are more abundant in neural tissues, ALA contributes to overall fatty acid balance and may support cognitive function indirectly through its conversion pathways and anti‑inflammatory effects. Studies indicate potential benefits of ALA intake in reducing inflammatory markers in conditions such as asthma and rheumatoid arthritis, though further robust clinical trials are needed. While the conversion of ALA to EPA and DHA is limited, habitual dietary intake of ALA contributes meaningfully to overall omega‑3 status, especially in populations with low fish consumption or plant‑based diets. Nutrition authorities emphasize the importance of including ALA‑rich foods to support cardiovascular, skin, and systemic health, although reliance solely on ALA for EPA/DHA needs may be insufficient for optimal anti‑inflammatory and neural outcomes.

Adequate intake levels for alpha‑linolenic acid (ALA) have been established by nutrition authorities to guide dietary consumption, reflecting the essential nature of this omega‑3 fatty acid. According to NIH guidance, ALA intakes recommended per day are stratified by life stage and sex. For adult men, an Adequate Intake (AI) of 1.6 grams per day is advised, while adult women are recommended to consume 1.1 grams per day. During pregnancy, the AI increases to approximately 1.4 grams, and during lactation it is approximately 1.3 grams per day. Children and adolescents have age‑specific intake recommendations; for example, boys aged 9–13 years are recommended to consume about 1.2 grams per day while girls aged 9–13 years have a recommendation of about 1.0 gram per day. These intake levels are designed to ensure sufficient ALA for maintenance of normal physiological functions and to support the limited conversion to EPA and DHA, although direct dietary sources of EPA and DHA are recommended when possible. It is important to highlight that these values are Adequate Intakes, not Recommended Dietary Allowances (RDAs), because evidence insufficient to define a precise RDA exists—therefore the AI represents a level assumed to ensure nutritional adequacy. Several factors influence individual needs for ALA. Total dietary fat intake, the ratio of omega‑6 to omega‑3 fatty acids, and metabolic differences affect how much ALA is needed to achieve beneficial effects. Diets high in omega‑6 fatty acids can inhibit the conversion of ALA to longer chain omega‑3s, potentially increasing the requirement for ALA itself or for direct EPA and DHA. Additionally, genetics, age, and health conditions such as chronic inflammation may alter fatty acid metabolism and influence needs. Optimal intake may therefore differ from the baseline AIs depending on health status and life stage. While ALA alone contributes to health outcomes, consuming a balance of omega‑3 fatty acids including EPA and DHA is recommended for comprehensive cardiovascular and neural support. Integrating ALA‑rich foods such as flaxseed, chia seeds, walnuts, and canola oil alongside marine omega‑3 sources can help individuals meet recommended intakes and support overall nutrient balance.

Deficiency of alpha‑linolenic acid (ALA) is uncommon in populations consuming balanced diets that include adequate sources of polyunsaturated fats; however, it can occur in individuals with severely restricted fat intake or malabsorption conditions. Because ALA is essential, inadequate intake may impair cell membrane function and reduce the availability of its metabolites EPA and DHA. Clinically, essential fatty acid deficiency often presents with dermatologic symptoms first. These may include dry, scaly skin, dermatitis, and impaired skin barrier function, as essential fatty acids are critical components of epidermal lipids. Additionally, hair loss and brittle nails may occur due to compromised tissue integrity. Neurological signs are less specific but can manifest as mood disturbances, cognitive impairment, or increased susceptibility to inflammatory conditions, reflecting the role of omega‑3 fatty acids in neural membrane composition and neurotransmitter regulation. Laboratory indicators of essential fatty acid deficiency include altered fatty acid profiles in plasma or serum and an increased triene:tetraene ratio, which signifies a shift away from omega‑3 toward omega‑6 metabolites. Reference ranges for plasma fatty acid profiles are not universally standardized, but diminished levels of ALA, alongside linoleic acid, often precede overt clinical signs. Severe essential fatty acid deficiency can also affect wound healing and immune responses, increasing susceptibility to infections and prolonging recovery from tissue injury. In infants, deficiency may present with growth retardation and developmental delays due to inadequate fatty acid supply for neurodevelopment. At‑risk populations include individuals with fat malabsorption disorders, those on extremely low‑fat diets, and individuals receiving long‑term parenteral nutrition without appropriate lipid supplementation. Prevalence of true ALA deficiency in the general population is low but may be underrecognized in settings where overall omega‑3 intake is minimal. Ensuring sufficient intake through ALA‑rich foods or supplementation can prevent deficiency and support broader fatty acid metabolism.

Alpha‑linolenic acid (ALA, PUFA 18:3 c) is widely present in plant‑based foods, especially seeds, nuts, and certain oils. Among the richest sources, flaxseed oil and flaxseeds provide exceptionally high amounts of ALA; one tablespoon of flaxseed oil can contain over 7 grams of ALA. Chia seeds and hemp seeds are also excellent sources, offering several grams of ALA per ounce or tablespoon, respectively. Walnuts are unique among tree nuts for their high ALA content, often providing more than 2 grams per ounce. Canola oil and soybean oil serve as versatile culinary sources of ALA, with approximately 1–2 grams per tablespoon. Edamame (young soybeans) and other legumes contribute modest amounts while adding protein and fiber. Additional plant sources include Brussels sprouts and green leafy vegetables such as spinach, although these contain lower amounts compared to seeds and nuts. Pumpkin seeds, perilla oil, and certain whole grains contribute to overall intake in mixed diets. Incorporating a variety of these foods into daily meals can help individuals meet Adequate Intake recommendations through whole food sources. Food preparation methods also influence ALA availability; for example, ground flaxseeds may offer improved digestibility over whole seeds, which can pass through the digestive tract intact if not processed. The balance of omega‑6 to omega‑3 fatty acids in the diet also affects ALA's utility, as high omega‑6 intake can competitively inhibit its conversion to longer chain omega‑3s. Therefore, emphasizing foods with favorable omega‑3 profiles such as flaxseed, chia, walnuts, and canola oil supports better metabolic outcomes. Regular consumption of these foods as part of balanced dietary patterns, such as Mediterranean or plant‑forward diets, aligns with public health recommendations aiming to increase omega‑3 intake and reduce chronic disease risk.

The absorption of alpha‑linolenic acid (ALA) occurs primarily in the small intestine, where dietary fats are emulsified by bile acids and incorporated into micelles for uptake into enterocytes. Within the enterocyte, ALA is re‑esterified and incorporated into chylomicrons for transport through the lymphatic system into the bloodstream. Factors enhancing absorption include concurrent intake of dietary fat, which stimulates bile secretion and micelle formation, facilitating ALA uptake. Conversely, low‑fat meals or conditions that impair bile production can reduce ALA absorption. Bioavailability is influenced by food matrix and form; for example, oils and ground seeds typically provide more readily available ALA than whole seeds, which may resist digestion and pass through the digestive tract with limited nutrient release. Fiber content also affects bioavailability; high soluble fiber can bind bile acids and fatty acids, potentially reducing absorption efficiency. Once absorbed, ALA enters systemic circulation where it may be incorporated into cell membranes or undergo elongation and desaturation to form longer chain omega‑3 fatty acids like EPA and DHA, though the conversion rate in humans is limited. Factors inhibiting this conversion include high intake of omega‑6 fatty acids, which compete for the same enzymes, as well as age, genetics, and metabolic conditions such as insulin resistance. Strategies to enhance overall omega‑3 status include consuming ALA alongside dietary sources of EPA and DHA, such as fatty fish or algal oil, or ensuring balanced omega‑6 to omega‑3 ratios. Timing of intake with meals that contain a mix of macronutrients can support efficient absorption, as mixed meals promote bile secretion and fat digestion.

Supplementation with alpha‑linolenic acid (ALA) may benefit individuals who struggle to consume adequate amounts through diet alone, such as those with limited intake of ALA‑rich foods or specific dietary patterns. ALA supplements are available primarily as flaxseed oil capsules, chia seed oil, or hemp seed oil formulations. Typical doses range from several hundred milligrams to a few grams per day, with products often standardized to provide 300–1000 mg of ALA per serving. Evidence from meta‑analyses suggests that ALA supplementation may modestly improve markers of cardiovascular health, particularly in individuals with overweight or obesity, though the effect sizes are smaller compared to EPA and DHA supplementation. Supplementation decisions should consider individual health goals; for cardiovascular support, combined intake of EPA/DHA along with ALA may offer superior benefits due to more potent anti‑inflammatory properties. Individuals with specific health conditions such as hypertriglyceridemia or chronic inflammation may derive benefit from tailored omega‑3 supplementation under clinical guidance. Safety is generally high for ALA supplements at typical doses found in foods, but high intakes, especially above 3 grams per day of combined omega‑3 fatty acids, can increase bleeding risk, particularly in those on anticoagulant therapy. Patients with prostate cancer or at high risk may avoid high‑dose omega‑3 supplementation due to mixed evidence regarding cancer risk. Pregnant and lactating women should prioritize obtaining adequate ALA from foods and consider DHA/EPA supplements as advised by healthcare providers, as conversion from ALA to DHA is limited.

No formal Tolerable Upper Intake Level (UL) has been established specifically for alpha‑linolenic acid (ALA), reflecting its safety at dietary levels. However, consuming very high amounts of omega‑3 fatty acids, including ALA, may pose risks. The FDA and nutrition authorities note that total omega‑3 intake (EPA + DHA) above 3 grams per day from supplements may increase bleeding risk; similar caution may apply when combining high supplemental ALA with anticoagulant medications. Excessive intake can also contribute to caloric imbalance due to the high energy density of fats, potentially leading to unwanted weight gain if overall energy intake is not adjusted. Some studies have raised concerns about very high dietary ALA and potential links to prostate cancer risk, though evidence remains inconsistent and not definitive. Monitoring overall fatty acid intake and maintaining balance with other essential fats is advisable. Individuals with fat malabsorption conditions should adjust intake under clinical guidance to avoid gastrointestinal discomfort.

Alpha‑linolenic acid (ALA) may interact with medications that affect blood clotting. High intakes of omega‑3 fatty acids can enhance the effects of anticoagulant and antiplatelet drugs such as warfarin, clopidogrel, and aspirin, potentially increasing bleeding risk. Patients on these medications should consult healthcare providers before initiating high‑dose ALA supplements. ALA’s influence on lipid metabolism may also interact with lipid‑lowering medications like statins, although this interaction is generally safe and may provide additive benefits.

Common Forms: Flaxseed oil capsules, Chia seed oil, Hemp seed oil

Typical Doses: 300 mg to 2 g ALA/day

When to Take: With meals for better absorption

Best Form: Oil form with meals containing fat

⚠️ Interactions: Warfarin, Aspirin, Clopidogrel